Valuation: Precision BioSciences, Inc.

Market Cap 183M 164M 151M 137M 257M 17.4B 261M 1.82B 720M 9.11B 688M 673M 28.74B P/E 2026 *
-1.84x
P/E 2027 * -2.45x
Enterprise Value 183M 164M 151M 137M 257M 17.4B 261M 1.82B 720M 9.11B 688M 673M 28.74B EV / Sales 2026 *
13.6x
EV / Sales 2027 * 20.7x
Free-Float
91.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day-2.06%
1 week+15.08%
Current month+6.07%
1 month+4.40%
3 months-9.41%
6 months-9.17%
Current year+59.62%
1 week 5.77
Extreme 5.77
6.92
1 month 5.72
Extreme 5.72
6.92
Current year 3.53
Extreme 3.53
9.62
1 year 3.53
Extreme 3.53
9.62
3 years 3.53
Extreme 3.53
19.43
5 years 3.53
Extreme 3.53
326.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 2021-10-14
Chief Tech/Sci/R&D Officer 53 2006-01-25
Director of Finance/CFO 45 2026-07-31
Director TitleAgeSince
Chairman 68 2020-10-31
Director/Board Member 65 2020-03-09
Director/Board Member 67 2021-04-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/28/26 Buy

Director

1,000 0.0042%
9/25/26 Buy

Director

2,609 0.0108%
9/25/26 Buy

Director

1,135 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%+15.08%-4.18%-25.53% 183M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.04%+3.68%+44.14%+139.24% 38.33B
Weighted average by Cap. +0.39%+2.74%+47.55%+158.49%

Financials

2026 *2027 *
Net sales 13.48M 12.04M 11.11M 10.08M 18.88M 1.28B 19.17M 134M 52.94M 670M 50.6M 49.52M 2.11B 8.88M 7.92M 7.31M 6.64M 12.43M 843M 12.62M 88.07M 34.84M 441M 33.3M 32.59M 1.39B
Net income -94.18M -84.08M -77.61M -70.43M -132M -8.94B -134M -935M -370M -4.68B -353M -346M -14.77B -96.95M -86.55M -79.89M -72.5M -136M -9.2B -138M -962M -381M -4.82B -364M -356M -15.2B
Net Debt - -
Projected Income Statement - Annual - Precision BioSciences, Inc.
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline comprises in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is an in vivo gene editing program which targets and eliminates covalently closed circular DNA (cccDNA), the sole source of viral replication, leading to sustained loss of pre-genomic RNA (pgRNA), the precursor for hepatitis B virus (HBV) DNA. ELIMINATE-B is designed to be a curative treatment for chronic hepatitis B infection.
Employees
67
Date Price Change Volume
26-10-23 US$6.640 -2.06% 275,533
26-10-22 US$6.780 +1.04% 132,428
26-10-21 US$6.710 +2.29% 231,040
26-10-20 US$6.560 +5.98% 213,655
26-10-19 US$6.190 +7.28% 176,469
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Precision BioSciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.640USD
Average target price
29.40USD
Spread / Average Target
+342.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Precision BioSciences, Inc.
  1. Stock Market
  2. Stocks
  3. DTIL Stock